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Edited by Richard MaraisAbstract Atherosclerotic plaques result from the excessive
deposition of cholesterol esters derived from lipoproteins and
lipoprotein fragments. Tissue macrophage within the intimal
space of major arterial vessels have been shown to play an impor-
tant role in this process. We demonstrate in a transfection system
using two human cell lines that the macrophage scavenger recep-
tor CD36 selectively elicited lipid uptake from Cu2+-oxidized
high density lipoprotein (HDL) but not from native HDL or
low density lipoprotein (LDL). The uptake of oxHDL displayed
morphological and biochemical similarities with the CD36-
dependent uptake of oxidized LDL. CD36-mediated uptake of
oxidized HDL by macrophage may therefore contribute to ath-
eroma formation.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The primary cause of heart disease and stroke is atheroscle-
rosis, a disease characterized by an accumulation of lipid laden
foam cells beneath the aortic endothelium. As a major precur-
sor of foam cells, macrophages are considered to lack the abil-
ity to limit the uptake of cholesterol and therefore the balance
of lipid ﬂux governs their development into foam cells [1]. Both
LDL and HDL are involved in cholesterol homeostasis and
both are potential sources of cholesterol esters (CE) that accu-
mulate in atherosclerosis [2]. However, the prevailing experi-
mental evidence suggests LDL that has undergone chemical
modiﬁcations including acetylation (ac) and oxidation (ox)
predominantly contributes to atheroma formation [3].
Because of their prime importance in regulating cholesterol
homeostasis, the cellular receptors for lipoproteins have been
intensively studied. Modiﬁed LDL are generally bound by dif-
ferent receptors than those that bind native lipoproteins.
Coined scavenger receptors, these are classiﬁed as either sub-
class A (SR-AI and SR-AII) or subclass B which includesAbbreviations: LDL, low density lipoprotein; HDL, high density lip-
oprotein; mAb, monoclonal antibody
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CD36 and its orthologue SR-BI can bind oxLDL and acLDL,
and transfection of either receptor confers this ability for the
binding and degradation of the modiﬁed lipoproteins [4–6].
Macrophages from double knockout mice for SR-A and
CD36 were poor in their degradation of modiﬁed LDL and
failed to accumulate CE suggesting these receptors were collec-
tively most relevant to the atherosclerotic risk [7]. However,
deletion of SR-A or CD36 on a susceptible apolipoprotein E
null background failed to prevent the in vivo occurrence of
foam cells suggesting other factors were involved [8]. In this re-
gard, the expression of SR-B1 in macrophages has been shown
in a protective role in atherogenesis [9] as have members of the
ABC-transporter family that promote eﬄux of lipids [1].
A number of reports have indicated that HDL is susceptible
to damaging structural modiﬁcations including oxidation [10].
Compelling evidence for the involvement of this process in the
etiology of atherosclerosis is the occurrence of oxidized HDL
within the intima of atheromatous plaques [11,12]. However,
the cellular receptors for oxHDL are poorly deﬁned with a sin-
gle report showing SR-B1 and LOX-1 on endothelial cells re-
ported to bind hypochlorite modiﬁed HDL [13]. Based on
the suggestion that oxidized HDL binding was mediated by
the same receptor(s) on macrophages that bind modiﬁed
LDL [14], we undertook this study to determine if the macro-
phage scavenger receptor CD36 could bind oxHDL.2. Materials and methods
2.1. Cell lines
Human MV3 melanoma and RD rhabdomyosarcoma were as previ-
ously described [15,16]. Human monocyte-derived macrophage from
peripheral blood were elicited with GM-CSF as previously reported
[17]. THP-1 pro-monocytic leukaemia cells were diﬀerentiated into
macrophage-like cells after 3–6 days treatment with 100 nM phorbol
ester (Sigma) [18].2.2. Analysis of CD36 expression
Levels of CD36 expression were determined by ﬂow cytometry using
indirect immunoﬂuorescent staining as previously described [16]. The
DFL1 values represent the median change in ﬂuorescence comparing
CD36 labeling versus control monoclonal antibody (mAb) values.2.3. Lipoproteins and accumulation assays
1,1 0-Diotadecyl-3-3-3 0-3 0-tetramethyllindocarbocyanine perchol-
orate (DiI)-labeled lipoproteins were purchased from Intracel Corpo-
ration (Rockville, MD). Oxidized HDL was prepared by dialysis
against 5–10 lM Cu2SO4 in PBS for 24–48 h before dialysis intoblished by Elsevier B.V. All rights reserved.
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jugated-lipoproteins were prepared using the Alexa Fluor 488 labelling
kit (Invitrogen, Australia). HDL was Alexa 488-labelled following the
in vitro oxidation reaction. All assays were conducted in situ with lipo-
proteins diluted in 0.5% foetal bovine serum. In some experiments cells
were pre-treated with monensin or nystatin (Sigma) or with controls
containing the carrier substance. Cells were harvested with trypsin–ver-
sene solution, ﬁxed and analysed using a FACScan ﬂow cytometer
(Becton-Dickinson) using the FL2 or FL1 emission ﬁlters for DiI
and Alexa 488, respectively. Mean ﬂuorescence measurements were
normalized against the control (no lipoprotein) condition and ex-
pressed as a relative change (DFL). Statistical analyses were performed
using either Student t-test or analysis of covariance as appropriate.
2.4. Visualization of lipoprotein accumulation
Cells seeded onto glass coverslips were incubated with lipoproteins
before ﬁxation and epiﬂuorescence microscopy as previously described
[19].3. Results
3.1. CD36 receptor function in the binding and uptake of DiI-
labelled LDL and oxLDL
MV3 melanoma and rhabdomyosarcoma (RD) cells are
CD36 negative but are derived from tissue sources that express
CD36 in vivo [15,16]. The transfected populations of MV3 and
RD cells expressed CD36 at levels consistent with the high lev-
els observed in human macrophage and macrophage-like
THP-1 cells. In contrast, the control vector-transfected cells
display negligible reactivity with a speciﬁc CD36 mAb (Fig. 1).
Control and CD36-transfected MV3 and RD cells were incu-
bated with increasing concentrations of DiI-labelled LDL or
oxLDL and the cell association of lipoprotein lipids measured
as DiI ﬂuorescence (DFL2). DiI is incorporated into the labile
lipid phase of the lipoproteins and can be used to monitor the
cellular association of lipids [20]. In both cell lines, a dose
dependent increase in DiI ﬂuorescence was observed after
incubation with DiI-LDL, however CD36-expression made
no diﬀerence to the accumulation (Fig. 2A). In contrast, while
control transfectants showed little uptake of DiI-oxLDL,
CD36 expression conferred a substantial increase in DiI-
oxLDL cellular accumulation. The uptake of DiI from LDL
but not oxLDL was also potently inhibited by 25 lM monen-
sin (Fig. 2B) that pharmacologically inhibits clathrin-coatedFig. 1. CD36 expression in vector and CD36-transfected MV3 melanoma
elicited human macrophage or THP-1 monocytic cells both before and after
proﬁles are control mAb (HB57; open proﬁle), anti-CD36 mAb (11H5; solidpits [21]. Conversely, 250 U/ml nystatin had no eﬀect on DiI-
association from LDL but strongly inhibited DiI-oxLDL up-
take in CD36-expressing cells (Fig. 2C).
Direct epiﬂuorescent examination of the cells showed cellu-
lar distribution of both DiI-LDL and the DiI-oxLDL uptake
mediated by CD36 was similar with the bulk of ﬂuorescence
occurring within intracellular vesicles clustered in a perinuclear
pattern (Fig. 2D). However at early time points the mode of
uptake for LDL was readily distinguished from oxLDL. DiI-
LDL treatment promoted the rapid appearance of vesicular
staining whereas DiI-oxLDL decorated plasma membrane
structures including ﬁlopodia and microvilli before gradually
becoming vesicular (data not shown).
3.2. CD36 facilitates cell binding of HDL but only promotes
selective lipid uptake from oxidatively damaged HDL
HDL was subjected to oxidation using Cu2SO4 and prepara-
tions of either DiI-HDL or DiI-oxHDL were assayed in the
same way as had been performed for DiI-LDL and DiI-
oxLDL. The control and CD36-expressing cells equally accu-
mulated DiI-HDL to high levels (Fig. 3A). Similar to the
results using LDL (Fig. 2A) the oxidation of HDL abolished
DiI-association in control cells. However, in the presence of
CD36, DiI-oxHDL was selectively accumulated (Fig. 3A).
While monensin had no eﬀect, nystatin pre-treatment was able
to signiﬁcantly inhibit CD36-mediated uptake of DiI-oxHDL
in MV3 cells but to a slightly lesser extent than that observed
for DiI-oxLDL (data not shown).
We next examined the cellular distribution of the labelled
lipoproteins in a time course experiment. Incubation of the
control and CD36-transfected MV3 cells with DiI-HDL gave
similar results with negligible ﬂuorescence observed at early
time points, shifting to a moderately intense diﬀuse plasma
membrane staining together with numerous clustered perinu-
clear intracellular vesicles (Fig. 3B and data not shown). In
the MV3 CD36 cells exposed to DiI-oxHDL, there was clear
plasma membrane ﬂuorescence after only 10 min, most nota-
bly in large bright clusters and also at the periphery of the cells
distributed into areas of ﬁlopodia and microvilli (Fig. 3B).
After 3 h, the ﬂuorescence was observed as mostly intense
punctate staining in a high proportion of cells with much of
the DiI-ﬂuorescence from oxHDL is seen to be contained with-and RD cell lines compared with CD36 expression seen in GM-CSF
diﬀerentiation for 3 days with phorbol esters (TPA). Flow cytometric
proﬁles) with the relative CD36 expression (DFL1) shown in brackets.
Fig. 2. Cellular association of DiI-LDL and DiI-oxLDL. (A) Analysis of vector and CD36-transfected MV3 melanoma and RD cell lines after 3 h at
37 C. Data are mean of duplicate samples with experiments repeated on three occasions. P, probability of signiﬁcance. (B) MV3-vector and CD36-
transfected cells were pre-treated with carrier substance (methanol) or 25 lM monensin for 30 min before measuring the uptake of 25 lg/ml of DiI-
LDL or DiI-oxLDL for 3 h in MV3-vector and MV3-CD36 cells, respectively. The data represent the means ± S.E. of triplicate determinations. (C)
Cells were pre-treated with carrier substance (DMSO) or 250 U/ml nystatin for 10 min before measuring the uptake DiI-LDL and DiI-oxLDL as
described for B. (D) Epiﬂuorescent micrographs of MV3 cells treated with 5 lg/ml of DiI-LDL or DiI-oxLDL for 3 h.
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the ﬂow cytometric assay (Fig. 3A) few control transfected
cells showed any obvious uptake of DiI-oxHDL after 3 h (data
not shown).
Since DiI is incorporated into the labile lipid phase of the
lipoproteins it cannot be used to distinguish between binding
and uptake of the HDL particle. To address this limitation
we also prepared Alexa Fluor 488-labelled HDL lipoproteins
where a ﬂuor is covalently conjugated to the apolipoprotein
[22]. HDL was then subjected to oxidation using Cu2SO4 to
make preparations of oxHDL. HDL and oxHDL labeled with
Alexa Fluor 488 were incubated with the MV3-transfectants
and showed that CD36 expression resulted in a signiﬁcant
accumulation of both HDL and oxHDL in a dose responsive
manner (Fig. 3C). The distribution of the Alexa labelled lipo-
proteins using epiﬂuorescent microscopy was then examined in
a time course experiment. Incubation of CD36-expressing cells
with either Alexa-HDL and -oxHDL resulted in the rapid
staining of a pattern of punctate ﬂuorescence (Fig. 3D). Over
time this pattern of staining intensiﬁed into strong clusters that
were most evidently distributed over the cell surface. In con-
trast, little ﬂuorescence was observed with control transfected
cells at any time (data not shown).
Competition assays were then used to assess the ability of
unlabelled lipoproteins to compete for the CD36-mediatedcellular binding of DiI-oxLDL and oxHDL. MV3.CD36 trans-
fectants were exposed to either DiI-oxLDL or -oxHDL for 3 h
in the absence or presence of excess unlabelled lipoproteins,
before harvesting and measuring cellular ﬂuorescence using
ﬂow cytometry. As shown in Fig. 4, CD36-mediated uptake
of DiI-oxLDL was eﬃciently blocked by excess unlabelled
oxLDL, but addition excess HDL, oxHDL and LDL also sig-
niﬁcantly inhibited cellular association to lesser extents. When
CD36-mediated uptake of DiI-oxHDL was similarly exam-
ined, both HDL and oxHDL reduced cellular ﬂuorescence
near equally. LDL also reduced oxHDL association whereas
oxLDL inhibition was less marked and not statistically signif-
icant. These results were also reﬂected in assays performed in
parallel on cells adherent to glass coverslips and examined
by epiﬂuorescent microscopy (not shown). Together these re-
sults suggest that binding of oxLDL and oxHDL by CD36
are probably not identical although with some of the oxHDL
binding appears to occur through common components shared
with native lipoproteins.
3.3. Oxidized HDL and investigations of foam cell formation
To investigate the functional properties of oxHDL in regard
to atheroma formation we tested the ability for it to promote
in vitro foam cell formation. Both GM-CSF elicited human
peripheral blood monocytes [17] and phorbol ester-treated
Fig. 3. (A) Cellular association of DiI-HDL and DiI-oxHDL in vector and CD36-transfected MV3 melanoma and RD cell lines after 3 h at 37 C.
Data are means of duplicate samples with experiments repeated on three occasions. P, probability of signiﬁcance. (B) Epiﬂuorescent micrographs of
MV3-CD36 cells treated with 5 lg/ml of DiI-HDL or DiI-oxHDL for 10 min or 3 h. (C) Cellular association of Alexa 488-HDL and Alexa 488-
oxHDL in vector and CD36-transfected MV3 melanoma cell lines as described for A. (D) Epiﬂuorescent micrographs of MV3-CD36 cells treated
with 5 lg/ml of Alexa 488-HDL or Alexa 488-oxHDL for 10 min and 3 h.
Fig. 4. Competition analysis comparing oxLDL and oxHDL uptake
in MV3 melanoma cells expressing CD36. Cells were incubated with
5 lg/ml of either DiI-oxLDL or DiI-oxHDL for 3 h at 37 C in the
absence or presence of excess unlabelled lipoprotein. Data are means
of triplicate samples ± S.E.M. *, P < 0.05.
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phage-like cells [18] were used for this assay since macrophages
are the primary target cell for atheroma development in vivo.
These cells express abundant CD36 protein on the cell surface(Fig. 1) and have been utilized as in vitro models of foam cell
formation [18]. After treatment with extended incubations of
oxidatively modiﬁed LDL or HDL from 1 to 6 days and at
concentrations of 50–250 lg/ml both oxLDL and oxHDL
proved highly toxic causing death to both cell types with fea-
tures of apoptosis. Native LDL or HDL did not induce cell
death (data not shown).4. Discussion
4.1. CD36 as a receptor for native and oxidized lipoproteins
It was ﬁrst reported by Calvo et al. [23] that CD36 expressed
in monkey COS-7 and Sf9 insect cells could function as a high
aﬃnity receptor for unmodiﬁed LDL and HDL, in addition to
its receptor role in the recognition of acLDL and oxLDL [4,5].
Cellular binding was clearly demonstrated in their study [23]
but it was not determined if the lipids derived from the native
lipoproteins were being internalized, which is a requisite step if
this function of CD36 was to contribute to lipid metabolism or
atherogenesis [1–3]. Subsequent investigations by other groups
have revealed that both rat and murine CD36 bound eﬃciently
to HDL, but the selective uptake of CE was poor compared to
SR-B1 [24,25]. Most importantly we observed that human
CD36-expression also did not promote increased lipid uptake
for either LDL or HDL in the context of a human cell back-
ground. Thus as for rat and mouse CD36 (that share 85%
and 83% homology to human, respectively), human CD36 also
appears to be ineﬀective in eliciting lipids from native lipopro-
teins. In contrast, it was shown that CD36 could accumulate
lipids derived from oxHDL.
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ter understand the mechanism of lipid uptake from oxHDL.
Biochemical experiments using, monensin, an inhibitor of
clathrin-coated pits [21] revealed that the mode of uptake of
lipids from DiI-oxHDL appeared inconsistent with the classi-
cal LDL receptor uptake occurring through this mechanism.
However certain similarities did exist between oxHDL and
oxLDL lipid uptake, as pre-treatment of the MV3 cells with
nystatin, a sterol binding agent that can perturb plasma mem-
brane rafts and caveolae [26], did inhibit CD36-dependent DiI-
oxLDL and DiI-oxHDL association. It has been reported that
CD36-oxLDL uptake occurs through a non-caveolar raft
mechanism [27] and since CD36 is known to be enriched in
membrane raft domains of MV3 cells [16] it is reasonable to
suggest that oxHDL may also interact with such domains.
Epiﬂuorescent microscopic studies then showed that CD36
promoted rapid cellular association of lipids from oxHDL.
This cellular association began rapidly with large bright clus-
ters that coalesced at the cell surface and on areas of ﬁlopodia
and after 3 h much of the DiI-ﬂuorescence was observed intra-
cellularly. Whether the entire oxHDL particle is internalized,
such as occurs with oxLDL [4] or just DiI is internalized as
the lipid phase cannot be determined by this method. We have
addressed this deﬁciency using HDL and oxHDL labeled with
Alexa 488 to show that CD36-promotes the speciﬁc cellular
association of both HDL and oxHDL. As was observed using
DiI-labelled reagents at early timepoints, the Alexa 488 ﬂuo-
rescence seemed more rapidly to accumulate from oxHDL
compared to HDL in CD36-expressing MV3 cells. However,
after 3 h the majority of the Alexa 488 signal was observed
in coalesced surface clusters in contrast to the predominantly
intracellular DiI ﬂuorescence. This demonstrates that CD36
can promote binding but not endocytosis of HDL/oxHDL
and that this interaction is suﬃcient to elicit lipid uptake from
oxHDL. It is therefore poignant to compare CD36 in this con-
text with SR-BI since it also functions to tether HDL to the
plasma membrane, although it is markedly more eﬃcient than
CD36 in the selective uptake of cholesterol esters from HDL
[24,25]. SR-BI does not endocytose HDL [28], rather it selec-
tively uptakes lipids through microvillar extensions of the plas-
ma membrane [29]. We similarly observed that oxHDL lipids
were initially elicited by CD36 through microvillar processes
suggesting a similar mechanism is at play.
4.2. Implications for oxidized HDL in the development of
atherosclerosis
Strong evidence now exists to suggest that HDL, in the form
of oxHDL, functions in a pro-atherogenic role. Studies of ani-
mals and humans have indicated that oxHDL is detected in
plasma [30,31] and that oxHDL is increased in hypertriglycer-
idemia, a risk factor for atherosclerosis [32]. Oxidized HDL
has also been identiﬁed within the intima of atheromatous pla-
ques [11,12]. A suggested mechanism for in vivo lipoprotein
damage is the myeloperoxidase (MPO) protein secreted by
polymorphs and monocyte/macrophages. As part of the
(MPO)-H2O2-halide reaction, secreted MPO can promote
reactions including oxidation of tyrosine, lipid peroxidation
and the oxidative intermediates hypochlorite (ClO) and
hypochlorous acid (HOCl) (see [10,11,33]). HDL has been
shown to undergo oxidative changes after incubation with
polymorphonuclear cells [34] and this system appears active
within the aortic wall giving rise to 3-chlorotyrosine modiﬁedHDL [11]. Both CD36 and SR-B1 have been shown to be
receptors for HOCl-modiﬁed LDL and the interaction with
HOCl-LDL could be strongly inhibited with Cu2+-oxidized
LDL suggesting there may be a common basis for recognition
[33]. We observed in this study that oxLDL was not particu-
larly eﬃcient in blocking lipid uptake from oxHDL indicating
that diﬀerences are likely to exist between the ligands in
oxLDL and oxHDL recognized by CD36.
In summary, we have demonstrated using a transfection
model that CD36 conferred the ability of cells to accumulate
HDL subjected to Cu2+-mediated oxidation. This process ap-
peared 2–4-fold less eﬃcient than CD36-mediated uptake
of oxLDL based on DiI ﬂuorescence. However, this ﬁnding
is likely to be physiologically relevant since any net increase
in the uptake of lipids will be signiﬁcant in the course of a dis-
ease that can take decades to manifest. We also described that
after longer term in vitro incubation with oxidized HDL, mac-
rophage were killed with these cells displaying features of
apoptosis. This is entirely consistent with previous reports
showing the toxic properties of oxidized HDL (e.g.[35]) and
suggests that further assessment of the proposed pro-atherosl-
erotic properties of oxHDL are best undertaken in an in vivo
model.
Finally, CD36 is also not the only likely receptor contribut-
ing to the uptake of oxHDL. Putative oxHDL receptor(s) were
identiﬁed in cultured human aortic endothelial cells (HAEC)
and major band was detected at 130 kDa which is too large
to represent either CD36 [12], SR-BI or LOX-1 [13]. Neither
should it be considered that the response of cells to oxHDL
is identical to that of oxLDL given a microarray study of genes
regulated by oxLDL versus oxHDL showed diﬀerential gene
expression in human macrophage [36]. Further work is there-
fore needed to evaluate the contribution of modiﬁed HDL
and its receptors in atherosclerosis.
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